Celldex Therapeutics, Inc.
- CLDX
- NASDAQ
- Biotechnology
- Antibody Therapeutics
- Immuno-Oncology
- Inflammation Treatments
$29.67
Today +7.77%Quote Oct 19, 2026, 08:00 PM UTC
−22.41%over the last month
Max drawdown −28.0%From 1-month high −22.4%3 months −16.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer.
Where the money comes from
Q2 2026 revenue $22,000
- Grant$15,00068.2%
- Service$7,00031.8%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
198
Founded
1983
Market value
$2.33B
Quote Oct 19
Floor
$29.37
1.0% below price
Resistance
$30.90
4.2% above price
Price vs analyst targets
20 analysts
Lowest target
$45.00Highest target
$100.00
$45.00Highest target
$100.00
- Price $29.67
- Average target $66.80
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 125% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CLDXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free